Keyoung Hansoo Michael
Known title: DirectorCIK: 0001824764
Associated companies
Transaction History
| KAPA | ▲ Buy | Grant | 19,084 | $0 | 10/8/2025 | View on chart |
| KAPA | ▲ Buy | Grant | 10,000 | $0 | 9/16/2025 | View on chart |
| KAPA | ▲ Buy | Grant | 19,084 | $0 | 10/8/2025 | View on chart |
| KAPA | ▲ Buy | Grant | 10,000 | $0 | 9/16/2025 | View on chart |
We use analytics to understand how market-wall is used. No personal data is sold.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 7, 2026
Kairos Pharma Reports Positive Phase 2 Data for ENV-105
Kairos Pharma announced positive, statistically significant interim efficacy data from a Phase 2 trial of ENV-105 for metastatic prostate cancer. The company noted the drug targets a specific resistance mechanism in the disease. This clinical update is the primary driver behind recent stock movement, occurring while the share price trades well below its 52-week high.
Kairos Pharma Reports Positive Phase 2 Data for ENV-105. Kairos Pharma announced positive, statistically significant interim efficacy data from a Phase 2 trial of ENV-105 for metastatic prostate cancer. The company noted the drug targets a specific resistance mechanism in the disease. This clinical update is the primary driver behind recent stock movement, occurring while the share price trades well below its 52-week high.